2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 588

Blacks with As Have Greater Disease Severity Than Whites
Abstract Number: 2795

Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Abstract Number: 1899

Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis
Abstract Number: 965

Blockade of TLR4 Signaling By TAK242 Ameliorates Experimental Organ Fibrosis
Abstract Number: 1510

Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
Abstract Number: 2194

Blue Digit Syndrome: The Rheumatologist’s Perspective
Abstract Number: 2793

BMP2 Requires TGF-Beta to Induce Osteophytes during Experimental Osteoarthritis
Abstract Number: 1017

BMP9-Induced pSmad1/5/8 Signaling and Chondrocyte Hypertrophy Are Effectively Inhibited By TGFβ1
Abstract Number: 45

Body Mass Index Across the Lifespan and Lifetime Incidence of Gout in Men
Abstract Number: 338

Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Abstract Number: 1424

Bone Erosions in Patients with RA: Exploring the Impact of the Anatomy of Interest on the Relationship Between MRI and X-Ray Erosion Detection
Abstract Number: 2130

Bone Microstructure in Patients with Cutaneous Psoriasis and No History of Psoriatic Arthritis Shows Bone Anabolic Changes at a Greater Extent Than in Healthy Controls
Abstract Number: 1683

Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon
Abstract Number: L20

BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study
Abstract Number: 2657

Brain Gray and White Matter Volume Losses and Their Associations with Glucocorticoid Use in Patients with Newly Diagnosed Systemic Lupus Erythematosus (SLE) – a Prospective MR Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].